A new area for the management of hyperkalaemia with potassium binders: clinical use in nephrology

Patrick Rossignol*

Université de Lorraine, Inserm, Centre d’Investigations Cliniques- Plurithématique 1433, Inserm U1116, CHRU Nancy, and F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Association Lorraine de Traitement de l’Insuffisance Rénale, Nancy, France

KEYWORDS
Hyperkalaemia; Chronic kidney disease; Potassium binders; Prognosis-randomized trials

Chronic kidney disease (CKD) patients and more so CKD patients treated with renin-angiotensin-aldosterone system inhibitors (RAASi) are prone to experience hyperkalaemia, a condition associated with an increased risk of death. This represents a true dilemma in daily practice since RAASi are the cornerstones of nephroprotective and cardioprotective strategies in CKD patients, as well as in hypertensive patients with or without CKD. The recent availability in the USA and EU of the potassium-binding resin Patiromer, together with sodium zirconium cyclosilicate (SZC), which was more recently approved in the EU and the US, may lead to a paradigm shift both in the treatment of hyperkalaemia and in enabling RAASi maintenance. Whether potassium normalization, potentially combined with a RAASi maintenance strategy, may translate into improved cardiovascular and renal outcomes needs be tested prospectively.

Introduction

There is a current dilemma in the nephrology field with regard to renin-angiotensin-aldosterone system inhibitors (RAASi) use. These drugs, especially angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB), are indeed the cornerstones of nephroprotective strategies, as acknowledged by current guidelines1-3 and of cardiovascular (CV) protection strategies. RAASi are furthermore one of the five first-line antihypertensive drugs,4 and one of the compelling components of the triple antihypertensive therapies for managing resistant hypertension, as recommended by international guidelines.5 However, hypertensive patients with/without chronic kidney disease (CKD) and CKD patients treated with RAASi are more prone to experience hyperkalaemia, a condition associated with an increased risk of death. In the hyperkalaemia setting, current guidelines consistently recommend to not start, to down-titrate or to discontinue RAASi, depending on its severity.1,3,6-8 The availability in the USA and in the EU of the potassium-binding resin Patiromer,9 as well as of sodium zirconium cyclosilicate (SZC), now approved in the EU,10 and in the US (https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207078s000lbl.pdf), may lead to a paradigm shift in treating hyperkalaemia and enabling RAASi maintenance.

Position of the problem: the burden of hyperkalaemia in the nephrology setting

Observational data mostly report a U-shape association between serum potassium and death, with hypokalaemia and hyperkalaemia being associated with worse outcomes in various patient populations including general,11,12 hypertensive,13 high CV risk,11 CKD,11 and acute14,15 and chronic heart failure16,17 populations (the latter two conditions associated with CKD in one-third of patients18) In a large US health system gathering data from 194 456 outpatients, hyperkalaemia above 5 or 5.5 mmol/L occurred in 10.8% and 2.3% of all patients over a 3-year period. The risk of experiencing hyperkalaemia was logically higher among patients with more frequent potassium measurements and with lower estimated glomerular filtration rate (eGFR).
Among patients with eGFR <30 mL/min/1.73 m² who had ≥4 potassium measurements per year, 62.1% experienced potassium >5 mmol/L and 29.9% experienced potassium >5.5 mmol/L. In an individual-level data meta-analysis of 27 international cohorts (10 general population, 7 high CV risk, and 10 CKD) including 1 217 986 participants followed for a mean of 6.9 years, the prevalence of serum potassium >5.0 mmol/L and serum potassium >5.5 mmol/L was lower in individuals in general population/high CV risk cohorts (3.31% [95% confidence interval (CI) 3.28-3.34%] and 0.49% [95% CI 0.48-0.50%]) comparatively to individuals in the CKD cohorts [17.94% (95% CI 17.58-18.31%) and 4.23% (95% CI 4.03-4.42%)], respectively. The lowest risk of all-cause mortality was observed at serum potassium of 4-4.5 mmol/L. The relative risks associated with hyperkalaemia and hypokalaemia were similar in patients with various levels of kidney (dys)function. Risk relationships were similarly U-shaped for CV mortality and end-stage renal disease. The risk of experiencing hyperkalaemia also increases with lower eGFRs11,19 and higher microalbuminuria excretion,11 along with RAASi use.11,12,19 In a post hoc analysis of the Reduction of Endpoints in non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL) trial, a randomized, double-blind trial comparing the effects of losartan vs. placebo in addition to conventional antihypertensive medication in patients with Type 2 diabetes and nephropathy, Miao et al.20 showed that increased serum potassium concentrations ≥5.0 mmol/L were associated with an increased risk of doubling serum creatinine or end-stage renal disease, independent of baseline renal function, and other important predictors of renal outcomes. The pathophysiological mechanism whereby increased serum potassium levels affect renal outcomes is however poorly understood. A decrease in renal perfusion (regardless of its cause, including RAASi) and early tubulo-interstitial damage may impair renal potassium excretion, even though renal function is only mildly depressed. This situation may lead to an imbalance in renal potassium/sodium handling that may further damage the tubules, thereby subsequently contributing to a further decline in renal function.20

Current international CKD guidelines recommend using RAASI in order to achieve nephroprotection, since they enable preserving kidney function and delay the progression to ESRD in CKD. Indeed, these agents are able to slow the progression of kidney disease,2,3 and to reduce proteinuria.1,3 Their use is valuable in CKD and indicated in proteinuria,1,2 with known beneficial effects in diabetic nephropathy. Better renal outcomes have furthermore been observed with higher RAASI doses.21,22 Proteinuria can be lowered by dual renin angiotensin aldosterone blockade with ACEI and ARBs or with direct renin inhibitors to a greater extent than monotherapy.23 While this combination may potentially preserve renal function in patients with diabetes and CKD to some extent, according to a network meta-analysis,24 this combination also increases the risk of hyperkalaemia, hypotension, and acute renal failure.24 Therefore, dual RAS blockade is discouraged by both NICE and ESH guidelines as well as the European Medicines Agency.1,25 RAASI are more effective at reducing kidney function decline than other blood pressure lowering drugs.3 However, the use of RAASI drugs is inherently associated with a risk of hyperkalaemia owing to their pharmacological properties, leading to aldosterone inhibition. Should hyperkalaemia arise, it is advised by current nephrology and cardiology guidelines to not initiate, to down-titrate or to discontinue RAASI, according to its severity.1,3,6-8 In the aforementioned US health system, the most common medication changes were discontinuation/dose reduction of RAASI. For instance, compared with a control with a potassium measurement <5 mmol/L, a patient with a serum potassium >5.5 mmol/L had a 3.7-fold (95% CI 3.3-4.3) odds of ACEI/ARB discontinuation within the next 60 days.19

The approach to and treatment of patients with chronic hyperkalaemia is however currently undergoing significant change. Until recently, recommendations for patients with chronic hyperkalaemia have been to: (i) place them on a low potassium diet; (ii) eliminate potassium supplements and drugs that compromise renal function, such as non-steroidal anti-inflammatory drugs; (iii) initiate treatment with a non-potassium sparing diuretic, if indicated, or increase the dose if already on a diuretic, and (iv) reduce the dose or discontinue RAASI.6,16 However, reducing the dose of the RAASI or discontinuing the latter could place the patient with heart failure and reduced ejection fraction at increased risk of death, since major clinical trials have demonstrated a reduction in CV mortality and total death with RAASI treatment, leading to a Class I indication in major European and United States guidelines.7,8 In a large US database including more than 20 000 heart failure patients, nearly 60% who discontinued RAASI after an hyperkalaemic episode experienced an adverse outcome or mortality compared with 52% of patients on submaximum RAASI doses and 44% of patients on maximum doses (all comparisons P < 0.05). Heart failure patients on submaximum dose or who discontinued RAASI died twice as frequently as patients on maximum dose. Over 50% of the 43 388 patients with CKD Stages 3 to 4 who discontinued RAASi after an hyperkalaemic episode experienced an adverse outcome or died compared with 47.4% of patients on submaximum doses and 42.6% of patients on maximum doses (all comparisons P < 0.05). Mortality was also recorded in 9.8% of patients with CKD Stages 3 to 4 on maximum RAASI doses compared with 20.3% of patients on submaximum doses and 22.4% of patients who discontinued therapy after an hyperkalaemic event.27 Whether alternative hyperkalaemia mitigation strategies (potassium diet restriction, potassium binders, bicarbonates, non-potassium sparing diuretics) may enable achieving better clinical and kidney outcomes has yet to be tested in dedicated randomized trials. Interestingly, we recently conducted a hospital-based, prospective, multi-centre cohort study, the French NephroProStudy test, comprised of 2084 adult CKD patients Stages 1-5, the latter of whom were non-dialysed. These patients received optimized nephrologist care with a reinforced follow-up, providing nephrologists with a large set of blood and urine tests to assess each patient’s metabolic complications and CV risk at yearly intervals. Laboratory findings reported all relevant abnormal values, such as plasma potassium <3.5 or >5.0 mmol/L, together with a reminder of current

A new area for the management of hyperkalaemia with potassium binders A49
A new era for hyperkalaemia management with the advent of new potassium binders, and future directions/indications?

Sodium or calcium polystyrene sulfonate (SPS or CPS) are cation exchange resins that remove potassium via the gastrointestinal tract. These compounds were approved decades ago at a time when the concept of evidence-based medicine was not yet invented, i.e., in the absence of adequately-designed randomized controlled trials. SPS has long been prescribed to reduce serum potassium, although its tolerability is poor, having been associated with colonic necrosis, while its onset of action and degree of potassium lowering is unpredictable. \( ^{31,32} \) Furthermore, in patients with volume overload, the use of SPS may be associated with volume expansion and the development of manifest heart failure since SPS exchanges potassium for sodium. \( ^{33} \) A recent randomized, double-blind, placebo-controlled trial in 33 outpatients with CKD and mild hyperkalaemia (5.0-5.9 mEq/L) reported that 30 g SPS administered orally once daily for 7 days reduced serum potassium significantly more than placebo (\(-1.04 \text{ mEq/L, 95% CI } -1.37 \text{ to } -0.71\)), although the proportion of patients achieving normokalaemia at the end of treatment was not significantly different between treatment groups (73% SPS vs. 38% placebo, \( P = 0.07 \)). \( ^{34,35} \)

In contrast, two new potassium binders have been developed under the latest standards of drug development and have been recently approved: Patiromer (FDA approved in 2015, EMA approved in July 2017\( ^{9} \)) and sodium zirconium cyclosilicate (SZC) (EMA approved April 2018\( ^{10} \) and FDA approved May 2018\( ^{36} \)). Patiromer exchanges potassium for calcium while SZC exchanges potassium for sodium. Patiromer and SZC appear to be effective in lowering serum potassium in patients with hyperkalaemia, as demonstrated by relatively short-term (maximum 1 month) published and peer-reviewed studies for SZC, and up to 12 months for Patiromer. Patiromer and SZC appear to offer tolerability advantages over SPS, although direct comparative clinical studies have not been performed. Both SZC and Patiromer are free flowing powders that do not swell appreciably in the gastrointestinal tract. \( ^{35,37-39} \) Mild to moderate constipation has been reported in 1-11% of patients enrolled in the pivotal clinical trials. \( ^{35,40-43} \) No cases of colonic necrosis have been reported in clinical trials conducted to date. Other adverse effects include hypokalaemia (5-10%, depending on drug and dose) and hypomagnesaemia (3-7%, depending on Patiromer dose). \( ^{31,35} \) Patiromer has also been associated with mild constipation, \( ^{41} \) while SZC has been associated with an increased incidence of oedema. \( ^{35,42} \) The comorbidities of the patients enrolled in the Patiromer and SZC Phase II-III trials

### Table 1: Baseline comorbidities across Patiromer Phase II-III trials

| Number of patients with the following comorbidities or treatment | Trial 2014\( ^{44} \) | Trial 2024\( ^{17,45} \) | Trial 2044\( ^{46} \) | Trial 20540 | Trial 30141 |
|---|---|---|---|---|---|
| Haemodialysis subjects (n=6) | PEARL-HF (n=104) | CKD with HF (n=63) | AMETHYST-DN (n=304) | OPAL-HK (n=243) |   |
| HTN (%) | 4 (67%) | 57 (55%) | 63 (100%) | 236 (97%) |   |
| CKD (%) | 30 (50%) | 102 (98%) | 63 (100%) | 243 (100%) |   |
| Any RAASi | 3 (50%) | 102 (98%) | 63 (100%) | 243 (100%) |   |
| Dual RAAS blockade | ? | ? | 1 (1.6%) | ? | 41 (17%) |

**CKD, chronic kidney disease; DT2, diabetes Type 2; HF, heart failure; HTN, hypertension; RAASi, renin angiotensin aldosterone system inhibitor.**
are summarized in Tables 1 and 2, respectively. As expected, a substantial proportion of the enrolled patients were CKD patients (including CKD Stage 5D hemodialysis patients for Patiromer) with a high prevalence of Type 2 diabetes, approximately 96% with hypertension in the Patiromer studies when documented (data not reported with SZC), thereby perfectly matching the clinical patient patterns typically encountered by nephrologists. Of note, more than 99% of patients enrolled in the Patiromer development studies were initially treated with a RAASi (approximately 70% for SZC studies). Exploratory analyses performed in the Patiromer Phase III trial showed that 32 patients (62%) in the placebo group comparatively to 9 (16%) in the Patiromer group required an intervention to manage a recurrence of hyperkalaemia; at the end of the randomized withdrawal phase, 44% in the placebo group compared to 94% in the Patiromer group were still receiving RAASi. Interestingly, in the PEARL-HF Phase II trial conducted in heart failure patients with either CKD or a history of hyperkalaemia resulting in discontinuation of a RAASi and/or beta-adrenergic blocking agent, Patiromer use vs. Placebo led to a lower incidence of hyperkalaemia (7.3% Patiromer vs. 24.5% placebo, \(P = 0.015\)) and to a higher proportion of patients on spironolactone 50 mg/day (91% Patiromer vs. 74% placebo, \(P = 0.019\)). In patients with CKD \((n = 66)\), the incidence of hyperkalaemia was 6.7% with Patiromer vs. 38.5% with placebo \((P = 0.041)\). In the resistant hypertension and CKD setting, i.e. a population particularly prone to dismal outcomes, the ongoing randomized, double-blind, placebo-controlled AMBER study of Patiromer for the enablement of spironolactone use as the fourth antihypertensive drug for blood pressure control in patients with resistant hypertension and CKD (eGFR 25 to 45 mL/min/1.73 m²) aims to determine whether Patiromer treatment, used concomitantly with spironolactone, will result in a more persistent use of the mineralocorticoid receptor antagonist spironolactone through prevention of hyperkalaemia and lead to improved blood pressure control. More broadly, whether a strategy of RAASi maintenance whilst using new potassium binders in CKD patients presenting hyperkalaemia or RAASi uptitration in patients with hypokalaemia may ultimately translate into better cardiorenal outcomes warrants dedicated clinical trials (Figure 1, reprinted from Pitt and Rossignol). Of utmost importance is the necessity of potassium and creatinine monitoring, given the increased risk of death in patients with CKD and in hypertensive patients with/without CKD, both with mild hypo- and hyperkalaemia. One might also reconsider current recommendations for the monitoring of serum potassium. There are guideline recommendations for the frequency of potassium monitoring in patients with heart failure administered a RAASi as well as suggestions regarding the frequency of potassium monitoring in patients with hyperkalaemia receiving a potassium-lowering agent. These suggestions are based on

---

**Table 2** Baseline comorbidities or treatment across SZC Phase II-III trials

| Number of patients with the following comorbidities or treatment | ZS-002\(^{47}\) (\(n = 90\)) | ZS-003\(^{41}\) (\(n = 753\)) | HARMONIZE, or ZS-004\(^{42}\) (\(n = 258\)) |
|-----------------------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|
| DT2 (%)              | 50 (56%)                    | 451 (59.9%)                 | 170 (66%)                   |
| HF (%)               | ?                           | 300 (39.8%)                 | 94 (36%)                    |
| HTN (%)              | ?                           | ?                           | ?                           |
| CKD (%)              | 90 (100%)                   | 561 (74.5%)                 | 169 (66%)                   |
| Any RAASi            | 56 (62%)                    | 502 (66.7%)                 | 180 (70%)                   |
| Dual RAAS blockade   | 10 (11%)                    | ?                           | ?                           |

CKD, chronic kidney disease; DT2, diabetes Type 2; HF, heart failure; HTN, hypertension; RAASi, renin angiotensin aldosterone system inhibitor.

---

**Figure 1** Potential hypokalaemia and hyperkalaemia treatment patterns. CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; RAAS-I, renin-angiotensin-aldosterone system inhibitor. Reprinted from Pitt and Rossignol.
the experience gained in initiating these new agents in pivotal clinical trials,\textsuperscript{33} which led to a low prevalence of incident hypokalaemia overall and especially in the trials with Patiromer, while reports by the European Medicines Agency highlighted hypokalaemia (and oedema) side effects associated with S2C use which may affect up to 1 in 10 people\textsuperscript{10} vs. side-effects associated with Patiromer use, including the digestive system (constipation, diarrhea, abdominal pain and wind) and low blood magnesium, which may affect more than one in 100 people.\textsuperscript{10} However, data in the US and the EU suggest that these monitoring recommendations are often not followed and that many patients do not undergo any monitoring of their serum potassium or renal function after initiation of a RAASi.\textsuperscript{50,51}

In view of the known risk factors for both hypo- and hyperkalaemia, a more frequent monitoring of serum potassium and renal function should be considered in those patients with the aforementioned risk factors. However, the cost effectiveness and efficacy of any new potassium monitoring strategy will inexorably require further evaluation.\textsuperscript{52}

Conclusion

In conclusion, the new potassium binders obviously meet medical needs and open new avenues for the management of hyperkalaemia in the nephrology field. Furthermore, potassium binders may enable RAASi optimization, as already shown with Patiromer.\textsuperscript{41,45} However, whether this strategy, along with potassium normalization, may translate into improved CV and renal outcomes needs to be tested prospectively.\textsuperscript{52}

Acknowledgements

The author thanks Mr Pierre Pothier for the editing. Patrick Rossignol is supported by the French National Research Agency (FIGHT HF programme ANR-15-RHU-0004) and by the French PIA project “Lorraine Université d’Excellence”, reference ANR-15-IDEX-04-LUE.

Conflict of interest: Personal fees (consulting) from Novartis, Relypsa, AstraZeneca, Grünenthal, Idorsia, Stealth Peptides, Fresenius, Vifor Fresenius Medical Care Renal Pharma, Vifor and CTMA; lecture fees from Bayer and CVRx; cofounder of CardioRenal.

References

1. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43:51-290.

2. Group. KDIGO CKD. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1-110.

3. Excellence. NlfHaC. Chronic kidney disease (CG182): chronic kidney disease in adults: assessment and management. http://www.nice.org.uk/CG182 (1 September 2018).

4. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Gaidertz S, Grobbel DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruppe LA, Schmieder RE, Sirnes PA, Sleight P, Wassmann M, Waeber B, Zoccali C, London GM, Stengel B, Fouque D, ERA-EDTA EURECA-m working group; Red de Investigación Renal (REDINREN) network; Cardiovascular and Renal Clinical Trials (F-CRIN INCRCT) network. The double challenge of resistant hypertension and chronic kidney disease. Lancet 2013;386:1588-1598.

5. Heart Failure Society of America. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Gertz MA, Gheorghiade M, Hunt SA, Oparil S, Ponikowski P, Rosano GM, Windecker S, Tendera M, Torbicki A, Wijns W, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knutti J, Kohl P, Lancellotti P, Linhart A, Nihoyannopoulos P, Pieske MFP, Ponikowski P, Sirnes PA, Tamargo JL, Tendler M, Torbicki A, Wijnandes S, Clement DL, Coca A, Gillebert TC, Tendler M, Rosel AE, Ambrosioni E, Anker SD, Bauschert S, Hitt J, Cuatrecasas M, Defeurey M, De Ge, Dermoumou GA, Erdine S, Farsang C, Funcke- Brentano C, Gerc V, Germano G, Giesen S, Haller H, Hoes AW, Jordan K, Kahan T, Komajda M, Lavecchia D, Malhotra H, Olsen MH, Ostgren J, Parati G, Perk J, Polanov J, Popescu BA, Reina R, Ryden L, Sireko Y, Stanton A, Struttkjer-Boudier H, Tsoulis C, van de Borne P, Vlachopoulos C, Volpe M, Wood DA. 2013 ESC/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-2219.

6. Rossignol P, Massy ZA, Azziz M, Bakris G, Ritz E, Covin A, Goldsmith D, Heine GH, Kager J, Kanbay M, Mallamaci F, Ortiz A, Vanholder R, Wiecek A, Zoccali C, London GM, Stengel B, Fouque D, ERA-EDTA EURECA-m working group; Red de Investigación Renal (REDINREN) network; Cardiovascular and Renal Clinical Trials (F- CRIN INCRCT) network. The double challenge of resistant hypertension and chronic kidney disease. Lancet 2015;386:1588-1598.

7. Heart Failure Society of America. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Gertz MA, Gheorghiade M, Hunt SA, Oparil S, Ponikowski P, Rosano GM, Windecker S, Tendera M, Torbicki A, Wijns W, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knutti J, Kohl P, Lancellotti P, Linhart A, Nihoyannopoulos P, Pieske MFP, Ponikowski P, Sirnes PA, Tamargo JL, Tendler M, Torbicki A, Wijnandes S, Clement DL, Coca A, Gillebert TC, Tendler M, Rosel AE, Ambrosioni E, Anker SD, Bauschert S, Hitt J, Cuatrecasas M, Defeurey M, De Ge, Dermoumou GA, Erdine S, Farsang C, Funcke-Brentano C, Gerc V, Germano G, Giesen S, Haller H, Hoes AW, Jordan K, Kahan T, Komajda M, Lavecchia D, Malhotra H, Olsen MH, Ostgren J, Parati G, Perk J, Polanov J, Popescu BA, Reina R, Ryden L, Sireko Y, Stanton A, Struttkjer-Boudier H, Tsoulis C, van de Borne P, Vlachopoulos C, Volpe M, Wood DA. 2013 ESC/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-2219.
A new area for the management of hyperkalaemia with potassium binders

15. Legrand M, Ludes PO, Massy Z, Rossignol P, Parenica J, Park JJ, Ishihara S, AliHabib KF, Maggioni A, Miro O, Sato N, Cohen-Solal A, Fairman E, Lassus J, Harjola VP, Mueller C, Peacock FW, Choi DJ, Plaisance P, Spinjar J, Kosiborod M, Mebazaa A, Gayat E; GREAT (Global Research on Acute Conditions Team) Network and INI-CRCT (Investigation Network Initiative-Cardiovascular and Renal Clinical Trials) Study Group. Association between hyper- and hyperkalaemia and outcome in acute heart failure patients: the role of medications. Clin Res Cardiol 2018; 107:214-221.

16. Alldahl M, Jensen AC, Davidsen L, Erik森 MS, Moller Hansen S, Nielsen BJ, Krogerob M, Kober B, Torp-Pedersen C, Sogaard P. Associations of serum potassium levels with mortality in chronic heart failure patients. Eur Heart J 2017; 38:2890-2896.

17. Nunez J, Bayes-Genis A, Zannad F, Rossignol P, Nunez E, Bodi V, Minana G, Santas E, Chorro FJ, Molarr A, Carratala A, Navarro J, Gorriz JL, Lupon J, Husser O, Metra M, Sanchis J. Long-term potassium monitoring and dynamics in heart failure and risk of mortality. Circulation 2018;137:1320-1330.

18. Damk N, Valente MA, Voors AA, O'Connor CM, van Veldhuijen DJ, Hilllege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 2014;35:455-469.

19. Chang AR, Sang Y, Lehky J, Yahya T, Kirchner HL, Inker LA, Matsushita K, Ballew SH, Corehs J, Grams ME. Antihypertensive medications and the prevalence of hyperkalaemia in a large health system. Hypertension 2016;67:1181-1188.

20. Miao Y, Dobre D, Heerspink HJ, Brenner BM, Cooper ME, Parving HH, Shanifah S, Grobbbe D, de Zeeu D. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Antiiotin II Antagonist Losartan (RENAAL) trial. Diabetologia 2011;54:44-50.

21. Basi S, Lewis JB. Microalbuminuria as a target to improve cardiovascular and renal outcomes. Am J Kidney Dis 2006;47:927-946.

22. Blacklock CL, Hirst JA, Taylor KS, Stevens RJ, Roberts NW, Farmer AJ. Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in Type 2 diabetes: a meta-analysis. Diabet Med 2011;28:1182-1187.

23. Susantiptapong P, Sewardinhah B, Balik EM, El-Shahawy MA, Roger SD, Jaber BL. Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis. Am J Hypertens 2013;26:424-441.

24. Palmer SC, Mavridts N, Navarese E, Craig JC, Tonelli M, Salagnt G, Wiebe N, Rusmpo M, Wheeler DC, Strippoli GF. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet 2015;385:2047-2056.

25. Krause T, Lovbinclude M, McCormack T, Williams B; Guideline Development Guidance. Management of hypertension: summary of NICE guidance. BMJ 2011;343:d4891.

26. Pitt B, Rossignol P. Impact of hyperkalaemia and worsening renal function on the use of renin angiotensin aldosterone system inhibitors in chronic heart failure with reduced ejection fraction. Clin Pharmacol Ther 2017;102:389-391.

27. Epstein M, Reaven NL, Funk SE, Maughhey KJ, Oesterreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care 2015;21:212-220.

28. Wagner S, Metzger M, Flamant M, Houstier P, Haymann JP, Vrtovsnik F, Thvert E, Boffa J, Massy ZA, Stengob B, Rossignol P; NephroTest Study Group. Association of plasma potassium with mortality and end-stage kidney disease in patients with chronic kidney disease under nephrologist care—the NephroTest study. Nephrol Dial Transplant 2017;32:2112-2118.

29. Pitt B, Bakris GL. New potassium binders for the treatment of hyperkalaemia: current data and opportunities for the future. Hypertension 2015;66:73-78.

30. Zannad F, Rossignol P, Stough WG, Epstein M, Alonso Garcia M, D L A, Bakris GL, Butler J, Kosiborod M, Berman L, Mebazaa A, Rasmussen HS, Rulope LM, Stockbridge N, Thompson A, Wittes J, Pitt B. New approaches to hyperkalaemia in patients with indications for renin-angiotensin aldosterone inhibitors: considerations for trial design and regulatory approval. Int J Cardiol 2016;216:46-51.

31. Pitt B, Rossignol P. Potassium lowering agents: recommendations for physician and patient education, treatment reappraisal, and serial monitoring of potassium in patients with chronic hyperkalaemia. Clin Pharmacol Res 2016;11:585-591.

32. Lepage L, Dufour AC, Doiron J, Handfield K, Desforges K, Bell R, Vallie M, Savoie P, Perreau S, Laurin LP, Pichette V, Lafrance JP. Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalaemia in CKD. Clin J Am Soc Nephrol 2015;10:2136-2142.

33. Rossignol P, Legrand M, Kosiborod M, Hollenberg SM, Peacock WF, Emmett M, Epstein M, Kovesody CP, Yilmaz MB, Stough WG, Gayat E, Pitt B, Zannad F, Mebazaa A. Emergency management of severe hyperkalaemia: guideline for best practice and opportunities for the future. PharmacoRes 2016;113:585-591.

34. Food and Drug Administration (FDA). Lokelma: Highlights of Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207078s000lbl.pdf (1 September 2018).

35. Buyse JM, Huang IZ, Pitt B. PEARL-HF: prevention of hyperkalaemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. Future Cardiol 2012;8:17-28.

36. Stavros F, Yang A, Leon A, Nuttall M, Rasmussen HS. Characterization of structure and function of ZS-5, a K− selective ion trap. PloS One 2014;9:e116686.

37. McCullough PA, Beaver TM, Bennett-Guerrero E, Emmett M, Fonarow GC, Goyal A, Herzog CA, Kosiborod M, Palmer BF. Acute and chronic cardiovascular effects of hyperkalaemia: new insights into prevention and clinical management. Rev Cardiovasc Med 2014;15:11-23.

38. Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasie Y, Wadzicki R, Berman L, Bushinsky DA; AMETHYST-DN Investigators. Effect of patiromer on serum potassium level in patients with hyperkalaemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA 2015;314:151-161.

39. Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasie Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B, OPAL-HK Investigators. Patiromer in patients with kidney disease and hyperkalaemia receiving RAAS inhibitors. N Engl J Med 2015;372:211-221.

40. Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, Roger SD, Yang A, Lerman E, Singh B. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalaemia: the HARMONIZE randomized clinical trial. JAMA 2014;312:2223-2233.

41. Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, Block G, Qunibi W, Pergola P, Singh B. Sodium zirconium cyclosilicate in hyperkalaemia. N Engl J Med 2014;372:222-231.

42. Bushinsky DA, Rossignol P, Spiegel DM, Benton WW, Yuan J, Berman L, Witcos CS, Agarwal R. Patiromer decreases serum potassium and phosphate levels in patients on hemodialysis. Am J Nephrol 2016;44:404-410.

43. Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zawadzki R, Berman L, Rossignol P, Berman L, Lainscak M, Patiromer RD, Madani M. Impact of hyperkalaemia and worsening renal function on the use of nephrologist care—the NephroTest study. BMC Nephrol 2017;18:308.

44. Rossignol P, Lamiral Z, Frimat L, Girerd N, Duarte K, Ferreira J, Chnablu J; Castin N. Hyperkalaemia prevalence, recurrence and management in chronic haemodialysis: a prospective multicentre French regional registry 2-year survey. Nephrol Dial Transplant 2017;32:2112-2118.
use in the treatment of patients with resistant hypertension and chronic kidney disease: rationale and design of the AMBER study. *Am J Nephrol* 2018;48:172–180.

49. Pitt B, Rossignol P. The association between serum potassium and mortality in patients with hypertension: ‘a wake-up call’. *Eur Heart J* 2017;38:113–115.

50. Cooper LB, Hammill BG, Peterson ED, Pitt B, Maciejewski ML, Curtis LH, Hernandez AF. Consistency of laboratory monitoring during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure. *JAMA* 2015;314:1973–1975.

51. Nilsson E, De Deco P, Trevisan M, Bellocco R, Lindholm B, Lund LH, Coresh J, Carrero JJ. A real-world cohort study on the quality of potassium and creatinine monitoring during initiation of mineralocorticoid receptor antagonists in patients with heart failure *Eur Heart J Qual Care Clin Outcomes* 2018 [Epub ahead of print].

52. Pitt B, Rossignol P. Serum potassium in patients with chronic heart failure: once we make a U-turn where should we go? *Eur Heart J* 2017;38:2897–2899.